Session » SLE – Animal Models Poster

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 66

Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation

9:00AM-11:00AM: Abstract Number: 70

Angiotensin Receptor Blockers Prevent Loss of Dendritic Complexity in a Lupus Mouse Model of Cognitive Impairment

9:00AM-11:00AM: Abstract Number: 65

CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE

9:00AM-11:00AM: Abstract Number: 84

Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 67

Dermal Lymphatic Dysfunction Is Associated with Disease Activity in the MRL/lpr Lupus Model

9:00AM-11:00AM: Abstract Number: 83

Dysfunction of TRIM21 Promotes Aberrant Plasmablast Differentiation in Systemic Lupus Erythematosus Due to the Reduction of TRIM21-mediated Ubiquitylation of IRF5

9:00AM-11:00AM: Abstract Number: 76

Effect of Ifnα and Costimulatory Blockade on Brain Infiltration in a Model of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’

9:00AM-11:00AM: Abstract Number: 77

Flux Analysis Reveals Influence of Rab4 Expression on Mitochondrial and Pentose Phosphate Pathway Metabolism of Lupus T Cells

9:00AM-11:00AM: Abstract Number: 62

Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway

9:00AM-11:00AM: Abstract Number: 68

Inactivation of Transaldolase and HRES-1/Rab4 Predisposes to Hepatitis in a Mouse Model of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 71

Inhibition of Nuclear Pore Export Ameliorates Lupus via Modulation of Plasma Cell Generation and Survival

9:00AM-11:00AM: Abstract Number: 74

LILRA3 Promotes Lupus-like Chronic Graft-versus-Host Disease by Expansion of Follicular Helper T Cells and Anti-dsDNA Autoantibodies

9:00AM-11:00AM: Abstract Number: 61

Lyn-Deficient Murine Lupus Is Exacerbated by Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency

9:00AM-11:00AM: Abstract Number: 75

Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’

9:00AM-11:00AM: Abstract Number: 73

Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 64

Rab4A Controls mTOR Pathway Activation, Pro-inflammatory Lineage Development, and Disease Pathogenesis in Lupus-prone Mice

9:00AM-11:00AM: Abstract Number: 82

Rab4A Increases Mitochondrial Oxidative Stress and Glutathione Disulfide Accumulation That Underlie Neurobehavioral Changes in Lupus-Prone Mice

9:00AM-11:00AM: Abstract Number: 85

Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model

9:00AM-11:00AM: Abstract Number: 80

The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model

9:00AM-11:00AM: Abstract Number: 63

The Role of the Intestinal Microbiota in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 72

The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease

9:00AM-11:00AM: Abstract Number: 69

Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ

9:00AM-11:00AM: Abstract Number: 78

Ultraviolet Light Induces Increased T Cell Activation in Lupus-Prone Mice via Type I Interferon-Dependent Inhibition of T Regulatory Cells

9:00AM-11:00AM: Abstract Number: 79

Unique Primed Status of Microglia Under the Systemic Autoimmune Condition of Lupus-Prone Mice

9:00AM-11:00AM: Abstract Number: 81

UV Light Stimulates a Systemic Neutrophil Response Associated with Transient Kidney Injury

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].